Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA
Release Date: October 15, 2024
Expiration Date: March 31, 2026
Activity Overview
While there have been many therapeutic advances in the management of schizophrenia over the past few decades that have afforded many patients the opportunity for improved outcomes, several unmet needs persist. In particular, therapies are needed that better treat negative symptoms, address associated cognitive deficits, and maximize safety and tolerability. Ongoing development is aimed at addressing these unmet needs using novel strategies and therapeutic targets, and psychiatrists are looking to these future treatments to enhance schizophrenia outcomes.
This continuing education symposium from the 2024 Southern California Psychiatry Conference features leading clinician-researchers and patient videos that highlight aspects of living with the disorder, best practices for current management, and insights about the promise of future therapies.
This educational activity is an archive of the live/virtual symposium held on September 14, 2024.
Target Audience
This educational activity is directed toward psychiatrists, specialty nurse practitioners and physician assistants, and other clinicians involved in the management of patients with schizophrenia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the developments in understanding about the pathophysiology of schizophrenia
- Summarize the unmet needs in the treatment of patients with schizophrenia
- Assess clinical trial data for new and emerging agents for schizophrenia
- Design individualized treatment plans for patients with schizophrenia
Jonathan Meyer, MD
Voluntary Clinical Professor
Department of Psychiatry
University of California, San Diego
San Diego, CA
Disclosures: Consultant: 4MTX, Alkermes, BioXcel, Bristol Myers Squibb/Karuna, Cerevel, Delpor, ITCI, Neurocrine, Relmada, Sumitomo, Teva; Speakers Bureau: AbbVie, Alkermes, Axsome, ITCI, Neurocrine, Sumitomo, Teva, Vanda
Jacob Hanaie, PharmD, APh, BCPP
Director of Pharmacy
Kedren Acute Psychiatric Hospital and CMHC
Founder and Consulting Clinical Pharmacist
Clinical Pharmacy Interventions
Beverly Hills, CA
Disclosures: Consultant: AbbVie; Speakers Bureau: AbbVie, Alkermes, BioXcel, Intra-Cellular, Teva.
Sanjai Rao, MD, DFAPA
Clinical Professor of Psychiatry
Associate Residency Training Director
University of California, San Diego
Psychiatrist
Site Director, Residency Training
VA Medical Center
San Diego, CA
Disclosures: Speakers Bureau: Alkermes, Janssen, Neurocrine, Otsuka.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.